Skip to content

news

Press release | 2023-03-23

NEOGAP appoints new Chief Medical Officer in Swedish in English

NEOGAP Therapeutics announced today the appointment of Dr. Hanjing Xie as its new Chief Medical Officer (CMO), starting from 21 March. Dr. Xie will oversee NEOGAP’s clinical development programs and pipeline and provide medical oversight for the company’s first-in-human study. Dr. Xie is a highly experienced associate professor and senior consultant in oncology with diverse expertise from the pharmaceutical industry and university hospitals.

Press release | 2023-03-14

NEOGAP and Simsen Diagnostics enter collaboration to improve personalised cancer diagnostics in Swedish in English

NEOGAP Therapeutics and the cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalised cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in NEOGAP’s phase I/II clinical trial. The goal is to develop more precise and effective diagnostic tools for cancer.

Press release | 2023-02-06

NEOGAP receives CTA approval for a phase I/IIa clinical trial with its advanced cell therapy in Swedish in English

NEOGAP Therapeutics today announces that the Swedish Medical Products Agency has approved the company’s application to start a clinical trial of its personalised cell therapy against colorectal cancer. The phase I/IIa trial is planned to be initiated during the first half of 2023.

Press release | 2022-12-13

NEOGAP receives Notice of Allowance for European patent in Swedish  in English

NEOGAP Therapeutics AB announces today that the European Patent Office issued a Notice of Allowance covering ex vivo tumour selective T-cell expansion using EpiTCer® technology and compositions of cells prepared using the method.

Press release | 2022-06-14

NEOGAP Therapeutics’ patented method opens for new individualised treatment of MS in Swedish  in English

A recent study shows that a part of NEOGAP Therapeutics’ patented method for developing individualised immunotherapy for cancer treatment can also be used to identify which immune cells are involved in autoimmune diseases. In the study, four new target molecules for MS have been discovered.

Conference | 2022-11-02

ATMP-conference and SITC coming up

ATMP Sweden’s national conference is held in Stockholm, November 7 – 8. Sofia Berglund, Medical Doctor with a doctorate in immunology, and Principal Scientist at NEOGAP will be presenting: “Personalized tumour-trained lymphocytes (pTTL) –a novel, neoantigen-targeting T-cell therapy derived from tumour-draining lymph nodes”.

In the following days, it is time for the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, November 8 – 11. Anne-Laure Joly, Principal Scientist, and Scientific Lead Cell Therapy Development at NEOGAP, will present the accepted poster on NEOGAP’s cell product (pTTL) and the design of the first clinical study that is soon to be initiated.

– SITC is the leading cancer immunotherapy and tumour immunology conference and the highlight of the year in our field. It’s an excellent opportunity to meet and share best practices and learnings and to further develop relations and collaborations, says Anne-Laure Joly.

Press release | 2022-09-28

NEOGAP Therapeutics strengthens the board with two new members

NEOGAP Therapeutics AB, developing individualised immunotherapy for cancer treatment, strengthens the board with two new members. Anna Kälvemark and Steve Glavas both have experience in transforming start-ups into successful companies and contribute with cutting-edge expertise in regulatory activities and commercialisation of life science companies.

Conference | 2022-09-26

NEOGAP Therapeutics participates in the Annual Mayo Clinic Karolinska Institutet Scientific Research Meeting and presents two posters: pTTL and PIOR®

NEOGAP’s Principal Scientist and Scientific Lead Cell Therapy Development Anne-Laure Joly will present our cell therapy product, pTTL – personalised Tumour Trained Lymphocytes and the design of our first clinical study that is soon to be initiated.

NEOGAP’s Head of Neoantigen development Ola Nilsson will present PIOR® – Personalised Immuno-Oncology Ranking, our software using sequencing data from the patient and machine learning to select the most suitable neoantigens (tumour-specific mutations) for each patient.

Press release | 2022-06-14

NEOGAP Therapeutics’ patented method opens for new individualised treatment of MS in Swedish  in English

A recent study shows that a part of NEOGAP Therapeutics’ patented method for developing individualised immunotherapy for cancer treatment can also be used to identify which immune cells are involved in autoimmune diseases. In the study, four new target molecules for MS have been discovered.

Press release | 2022-05-05

New publication strengthens NEOGAP Therapeutics’ patented technology and shows that it can also be used for proliferation of T cells from blood in Swedish  in English

NEOGAP Therapeutics, which develops an individualised immunotherapy for treatment of cancer, presents in a publication together with researchers at Karolinska Institutet, preclinical data that further show that the company’s in-house developed technology EpiTCer® has the ability to effectively produce tumour-specific T cells.

Press release | 2022-03-24

The immunotherapy company NEOGAP Therapeutics AB contracts CRO for their first clinical trial for cancer (in Swedish)

NEOGAP Therapeutics AB, which develops an individualised immunotherapy for treatment of cancer, announces that Swedish CTC (Clinical Trial Consultants AB) has been chosen as the CRO (Contract Research Organisation) for the planned clinical phase I / IIa trial in colorectal cancer, which is expected to start in 2022.

Press release | 2022-02-28

NEOGAP Therapeutics AB, a Swedish immunotherapy company, raises 58 MSEK for a clinical trial for cancer (in Swedish)

Together with Sciety AB, a Swedish investor network, NEOGAP Therapeutics AB has completed a new issue of 58 million SEK. The capital raised will be used for a clinical first-in-human trial (phase I / IIa) in colorectal cancer, which is expected to start in 2022.